Noor Nader

Ms. Noor Nader

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NNNoor Nader
Noor Nader
SFStephen C. Frederico
Stephen C. Frederico
TMTracy Miller
Tracy Miller
SHSakibul Huq
Sakibul Huq
XZXiaoran Zhang
Xiaoran Zhang
CHConstantinos G. Hadjipanayis
Constantinos G. Hadjipanayis
Glioblastoma (GBM) is an aggressive primary brain tumor depicted by a cold tumor microenvironment, low immunogenicity, and limited effective therapeutic interventions. Its location in the brain, a highly immune-selective organ, acts as a barrier, limiting immune access and promoting GBM dissemination, despite therapeutic interventions. Currently, chemotherapy and radiation combined with surgical resection are the standard of care for GBM treatment. Although immune checkpoint blockade has revolutionized the treatment of solid tumors, its observed success in extracranial tumors has not translated into a significant survival benefit for GBM patients. To develop effective immunotherapies for GBM, it is vital to tailor treatments to overcome the numerous immunosuppressive barriers that inhibit T cell responses to these tumors. In this review, we address the unique physical and immunological barriers that make GBM challenging to treat. Additionally, we explore potential therapeutic mechanisms, studied in central nervous system (CNS) and non-CNS cancers, that may overcome these barriers. Furthermore, we examine current and promising immunotherapy clinical trials and immunotherapeutic interventions for GBM. By highlighting the array of challenges T cell-based therapies face in GBM, we hope this review can guide investigators as they develop future immunotherapies for this highly aggressive malignancy.

27 October 2026 in Cancer Discovery
Verified
Journal Article
Closed access
NNNoor Nader
Noor Nader
AGAlexandra Glathar
Alexandra Glathar
EBElaine V. Byrnes
Elaine V. Byrnes
MJMarion Joy
Marion Joy
TGTengziyi Ge
Tengziyi Ge
TBTullia C. Bruno
Tullia C. Bruno
B cells and their cellular neighborhoods, i.e., lymphoid aggregates (LA) and tertiary lymphoid structures (TLS), have not been extensively studied in melanoma brain metastases (BM) or lung adenocarcinoma BM, despite their prognostic value and role in immunotherapeutic responses. In this study, we evaluated the prognostic benefit and heterogeneity of B-cell infiltration and LA formation in more than 200 patients with melanoma BM or lung adenocarcinoma BM. We found that LAs were associated with increased intratumoral CD8+ T cells in melanoma BM compared with lung adenocarcinoma BM. Moreover, the presence of LAs was associated with an increased survival benefit in patients with melanoma BM but not in those with lung adenocarcinoma BM. Despite lacking canonical TLS hallmarks, LAs in BM contained proliferating B and T cells with the potential for effector function. Our work has solidified the need for the mechanistic investigation of intracranial B cells and the immune neighborhoods in which they reside. Significance: Among tumor metastases, patients with BM are considered to have the greatest mortality and very limited therapeutic options. This study uncovers immunologically active LAs as potential orchestrators of CD8+ T cell–mediated antitumor immunity in melanoma BM, emphasizing their potential as a therapeutic target within the unique tumor microenvironment of the brain.